CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. (August 2015)

• Record Type: Journal Article
• Authors: Ries, Carola H; Hoves, Sabine; Cannarile, Michael A; Rüttinger, Dominik
• Is Part Of: Current opinion in pharmacology. Volume 23(2015)
• Page Start: 45
• Page End: 51
• Publication Date: 2015-08
• Subjects: Pharmacology -- Periodicals; Pharmaceutical Preparations -- Periodicals; Drug Therapy -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Periodicals; 615.105
• DOI: 10.1016/j.coph.2015.05.008
• Languages: English
• ISSNs: 1471-4892

Abstract

Highlights: TAM promote tumor growth and efficiently suppress immune effector cells. Targeting TAM via the CSF-1/CSF-1R pathway is an attractive therapy for cancer. Can in vitro differentiated macrophages reflect patient-derived TAM? TAM depletion combined with standard- or immuno-therapies will be the way forward. Abstract : Macrophage infiltration has been identified as an independent poor prognostic factor for several cancer entities. In mouse tumor models macrophages orchestrate various tumor-promoting processes. This observation sparked an interest to therapeutically target these plastic innate immune cells. To date, blockade of colony stimulating factor-1 or its receptor represents the only truly selective approach to manipulate macrophages in cancer patients. Here, we discuss the currently available information on efficacy and safety of various CSF-1/CSF-1R inhibitors in cancer patients and highlight potential combination partners emerging from preclinical studies while considering the differences between mouse and human macrophage biology.